CIK 0002023658 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Bicara Therapeutics Inc.
Sign in to watch- Ticker
- BCAX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-468-4219
- Business address
- 116 HUNTINGTON AVENUE SUITE 703, BOSTON, MA, 02116
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $400,716
- in 1 filing, $401K under 10b5-1 plans
Net −$400,716. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-08 | Cohlhepp Ryan President, COO & Interim CEO | Option exercise 10b5-1 | +17,500 | $3.79 | $66K | 199,141 |
| 2026-09-08 | Cohlhepp Ryan President, COO & Interim CEO | Sale 10b5-1 | −14,058 | $22.77 | $320K | 185,083 |
| 2026-09-08 | Cohlhepp Ryan President, COO & Interim CEO | Sale 10b5-1 | −3,442 | $23.43 | $81K | 181,641 |
| 2026-09-08 | Cohlhepp Ryan President, COO & Interim CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −17,500 | 34,252 | ||
| 2026-08-12 | Larson Jennifer Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +285,000 | 285,000 | ||
| 2026-08-10 | Hyep Ivan Chief Financial Officer | Option exercise 10b5-1 | +12,500 | $3.79 | $47K | 142,355 |
| 2026-08-10 | Hyep Ivan Chief Financial Officer | Sale 10b5-1 | −12,500 | $27.97 | $350K | 129,855 |
| 2026-08-10 | Hyep Ivan Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −12,500 | 26,336 | ||
| 2026-08-10 | Mazumdar Claire Chief Executive Officer | Option exercise 10b5-1 | +10,000 | $3.79 | $38K | 372,152 |
| 2026-08-10 | Mazumdar Claire Chief Executive Officer | Sale 10b5-1 | −10,000 | $27.98 | $280K | 362,152 |
| 2026-08-10 | Mazumdar Claire Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,000 | 110,546 | ||
| 2026-08-10 | Cohlhepp Ryan President and COO | Option exercise 10b5-1 | +18,750 | $3.79 | $71K | 200,391 |
| 2026-08-10 | Cohlhepp Ryan President and COO | Sale 10b5-1 | −18,750 | $27.98 | $525K | 181,641 |
| 2026-08-10 | Cohlhepp Ryan President and COO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −18,750 | 51,752 | ||
| 2026-07-28 | Bender Jeremy Director | Grant or award · Stock Option (Right to Buy) | +38,950 | 38,950 | ||
| 2026-07-28 | Oliger Christy J. Director | Grant or award · Stock Option (Right to Buy) | +38,950 | 38,950 | ||
| 2026-07-10 | Mazumdar Claire Chief Executive Officer | Option exercise 10b5-1 | +10,000 | $3.79 | $38K | 372,152 |
| 2026-07-10 | Mazumdar Claire Chief Executive Officer | Sale 10b5-1 | −9,972 | $28.42 | $283K | 362,180 |
| 2026-07-10 | Mazumdar Claire Chief Executive Officer | Sale 10b5-1 | −28 | $29.68 | $831 | 362,152 |
| 2026-07-10 | Mazumdar Claire Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,000 | 120,546 |
Page 1 of 14 · 276 trades